sector medic suppli devic
 model updat ahead
messag schedul releas result tuesday februari
ahead report updat estim take account manag
recent comment regard near-term cvg headwind higher tax rate
top line growth set deceler below-trend ep growth like
tap next year see stock fulli valu current level reiter
model call third quarter revenu organ
previous current consensu cvg
segment lower heart failur revenu due recent chang
account around cath lab manag servic busi pressur
hvad due new heart transplant prioriti rule share loss follow heartmat
dt approv also moder aortic peripher forecast account
near-term pressur dcb use wake recent clinic controversi regard
long-term mortal impact paclitaxel-co peripher vascular product although
sens point like blow rel quickli full year
model call revenu organ essenti match current street
estim expect ep come in-lin consensu
midpoint manag guidanc
model call ep yoy total revenu
organ compar prior forecast
respect recent investor confer cfo karen parkhil note new regul
could push tax rate mr
parkhil indic compani would look way off-set headwind clear
point offset save might come one possibl solut could
acceler share buy-back although think would better serv enhanc
long-term growth profil rather deploy capit boost near-
term earn meantim manag remain commit long-term target
revenu growth annual ebita leverag goal
longer term continu see grower top
bottom line respect outlook slightli large-cap med-tech group
averag valuat gap rest
group expand recent ntm ep vs believ discount
warrant given near-term headwind face busi view
limit upsid potenti number next month result reiter
neutral rate
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
sinc compani work translat unmatch scale competit
advantag includ lead way healthcar landscap shift fee-for-
valu model re-envis mean centuri
devic compani pursu goal deliv econom valu uniqu
combin technolog servic go far beyond tradit purview
med-tech effort mix success date think concept
valu healthcar stay expect fee-for-valu transit play
meantim see execut around compani core financi target
primari driver valu creation front think manag recent
revis lrp set much achiev bar one could even allow compani
deliv upsid street expect time pipelin matur near-term
howev see stock fairli valu given growth trajectori
share current trade ntm ep estim
ntm ebitda repres discount large-cap med-tech group averag
respect view valuat appropri given medtron
project long-term growth profil top bottom line
respect lag behind broader sector averag better
opportun elsewher group view assign medtron neutral rate
upsid risk rate includ revenu growth exce forecast better-
than-expect execut margin target faster expect shift fee-for-
valu healthcar paradigm benefit compani superior scale play
medtron strength prove disrupt competitor
downsid risk rate includ clinic setback weaker-than-expect adopt
new product caus revenu fall short street estim better-than-expect
share gain competitor failur execut margin expans goal
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
